展品4.4
| (a) | |
|
|
|
| (b) |
1 |
| (c) | |
|
|
|
| (d) |
| (e) | |
|
|
|
| (f) | |
|
|
|
| (g) | |
|
|
|
| (h) | |
|
|
|
| (i) | |
|
|
|
| “Closing”在第2.8條中所指; | |
|
|
|
| (k) | |
|
|
|
| “commercially reasonable efforts”或“reasonable commercial efforts”,對於任何一方而言,意味着該方在符合商業實踐,不支付或承擔任何實質性的責任或義務的情況下采取其合理努力; | |
|
|
|
| (米) | |
|
|
|
| “j” | |
|
|
|
| “l” | |
|
|
|
| -3- |
2 |
| “p” | |
|
|
|
| (r) |
| (i) | |
|
|
|
| (ii) |
3 |
| (a) | |
|
|
|
| (b) | |
|
|
|
| (c) |
| (i) | |
|
|
|
| (ii) | |
|
|
|
| (iii) | |
|
|
|
| (iv) | |
|
|
|
| (v) |
| (d) |
| (i) |
4 |
| (ii) |
| (e) |
| (i) | |
|
|
|
| (ii) | |
|
|
|
| (iii) | |
|
|
|
| (iv) | |
|
|
|
| (v) |
| (f) | |
|
|
|
| (g) | |
|
|
|
| (h) | |
|
|
|
| (i) | |
|
|
|
| “Closing”在第2.8條中所指; |
5 |
| (k) |
| (i) | |
|
|
|
| (ii) | |
|
|
|
| (iii) | |
|
|
|
| (iv) | |
|
|
|
| (v) |
| “commercially reasonable efforts”或“reasonable commercial efforts”,對於任何一方而言,意味着該方在符合商業實踐,不支付或承擔任何實質性的責任或義務的情況下采取其合理努力; | |
|
|
|
| (米) |
| (i) | |
|
|
|
| (ii) |
6 |
| (iii) | |
|
|
|
| (iv) | |
|
|
|
| (v) |
| (n) |
| (a) | |
|
|
|
| (b) |
7 |
| (c) |
| (i) | |
|
|
|
| (ii) |
| (d) | |
|
|
|
| (e) | |
|
|
|
| (f) | |
|
|
|
| (g) |
| (a) | |
|
|
|
| (b) | |
|
|
|
| (c) | |
|
|
|
| (d) | |
|
|
|
| (e) |
8 |
| (f) | |
|
|
|
| (g) | |
|
|
|
| (h) | |
|
|
|
| (i) | |
|
|
|
| “Closing”在第2.8條中所指; |
| (k) |
| “commercially reasonable efforts”或“reasonable commercial efforts”,對於任何一方而言,意味着該方在符合商業實踐,不支付或承擔任何實質性的責任或義務的情況下采取其合理努力; |
9 |
| (米) | |
|
|
|
| “j” | |
|
|
|
| “l” | |
|
|
|
| -3- | |
|
|
|
| “p” |
10 |
| (a) | |
|
|
|
| (b) | |
|
|
|
| (c) | |
| (d) | |
|
|
|
| (e) | |
|
|
|
| (f) | |
|
|
|
| (g) |
11 |
| (a) | |
|
|
|
| (b) |
| (a) | |
|
|
|
| (b) |
12 |
| (a) | |
|
|
|
| (b) | |
|
|
|
| (c) | |
|
|
|
| (d) | |
|
|
|
| (e) | |
|
|
|
| (f) | |
|
|
|
| (g) | |
|
|
|
| (h) | |
|
|
|
| (i) |
13 |
| “Closing”在第2.8條中所指; | |
|
|
|
| (k) | |
|
|
|
| “commercially reasonable efforts”或“reasonable commercial efforts”,對於任何一方而言,意味着該方在符合商業實踐,不支付或承擔任何實質性的責任或義務的情況下采取其合理努力; | |
|
|
|
| (米) | |
|
|
|
| “j” | |
|
|
|
| “l” |
14 |
| (a) | |
|
|
|
| (b) | |
|
|
|
| (c) | |
|
|
|
| (d) | |
|
|
|
| (e) |
15 |
| (f) | |
|
|
|
| (g) |
| (a) | |
|
|
|
| (b) | |
|
|
|
| (c) | |
|
|
|
| (d) |
16 |
[本頁剩餘部分故意留空]
17 |
鑑於上述,各方當事人已於上述日期簽署本協議。
| fsd pharma公司 |
| |||
|
|
|
|
|
|
作者: |
| 作者: |
| ||
名稱: |
| 名稱: | Zeeshan Saeed |
| |
標題: | 首席執行官 |
| 標題: | 首席執行官 |
|
|
|
|
|
|
|
通訊地址: |
| 通訊地址: |
| ||
|
|
|
|
| |
|
| ||||
|
|
|
|
| |
| 電子郵件:Zsaeed@fsdpharma.com |
|
18 |